In one embodiment, the administration reduces tumor-associated angiogenesis. In one embodiment, total vessel area of vessels feeding a tumor is reduced by more than 40%, by 40% to 50%, by 50% to 60%, by 60% to 70%, or by more than 60%. In one embodiment, vessel length density of vessels feeding a tumor is reduced by more than 40%, by 40% to 50%, by 50% to 60%, or by more than 50%. In one embodiment, the number of vessels feeding a tumor is reduced by more than 40%, by 40% to 50%, by 50% to 60%, by 60% to 70%, by 70% to 80%, or by more than 70%. In one embodiment, the number of larger vessels is reduced by more than 40%, by 40% to 50%, by 50% to 60%, or by more than 50%. In one embodiment, the number of smaller vessels is reduced by more than 40%, by 40% to 50%, by 50% to 60%, by 60% to 70%, by 70% to 80%, or by more than 70%.
____
Find THAT....in any other companies cancer patent.

BOOOM !!!!